Christopher Slapak

Christopher Slapak

Plus aucun poste en cours
67 ans
Health Technology
Consumer Services
Health Services

Profil

Christopher Slapak worked as Vice President-Early Phase Development Oncology at Eli Lilly & Co. from 1996 to 2017.
He also worked as an Assistant Professor at Dana-Farber Cancer Institute, Inc. and as an Associate Professor-Clinical at The Indiana University School of Medicine.
In 2018, he became the Chief Medical Officer at Prelude Therapeutics, Inc. and in 2020, he became the Chief Medical Officer at Vor Biopharma, Inc. Dr. Slapak received his undergraduate degree from The Ohio State University and his doctorate degree from Pritzker School of Medicine.

Anciens postes connus de Christopher Slapak

SociétésPosteFin
VOR BIOPHARMA INC. Directeur Technique/Scientifique/R&D 06/05/2022
PRELUDE THERAPEUTICS INCORPORATED Directeur Technique/Scientifique/R&D 01/06/2019
ELI LILLY AND COMPANY Corporate Officer/Principal 01/12/2017
Corporate Officer/Principal -
Corporate Officer/Principal -
Voir l'expérience en détail de Christopher Slapak

Formation de Christopher Slapak

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

81

Relations au 1er degré

7

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées7

Health Technology

Health Services

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Christopher Slapak
- 40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT
🔇